$KROS News
Last published 6d ago
- 6d agoKROSKeros Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoKROSKeros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsGlobeNewswireFirst patient dosed in Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in September 2026Nominated KER-206, a novel ligand trap designed to bind select TGF-β ligands to regulate bone
- 3w agoAGIOIRONKROSPTGX+1A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayPR NewswireNEW YORK, Oct. 20, 2026 /CNW/ -- Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare
- 2mo agoKROSKeros Therapeutics Announces $5 Million Share Repurchase AuthorizationGlobeNewswireLEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and
- 3mo agoKROSKeros Therapeutics Reports Second Quarter 2026 Financial ResultsGlobeNewswireLEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and
- 3mo agoKROSKeros Therapeutics to Receive Development Milestone Payment from Partner TakedaGlobeNewswireLEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to
- 5mo agoKROSKeros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireLEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
- 6mo agoKROSKeros Therapeutics Reports Recent First Quarter 2026 Financial ResultsGlobeNewswireLEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 8mo agoKROSKeros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific ConferenceGlobeNewswireLEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 8mo agoKROSKeros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALSGlobeNewswireLEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 8mo agoKROSKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireLEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 8mo agoKROSKeros Therapeutics Appoints Charles Newton to its Board of DirectorsGlobeNewswireLEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 8mo agoKROSKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesGlobeNewswireLEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 11mo agoKROSKeros Therapeutics Announces Final Results of Tender OfferGlobeNewswireLEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), today announced the final results of its cash tender offer (the "Tender Offer") to repurchase up to
- 11mo agoKROSKeros Therapeutics Announces Preliminary Results of Tender OfferGlobeNewswireLEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), today announced the preliminary results of its cash tender offer (the "Tender Offer") to repurchase
- 1y agoKROSKeros Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswireLEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 1y agoKROSKeros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million SharesGlobeNewswireLEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 1y agoKROSKeros Therapeutics Announces Plan for Return of $375 Million in Excess CapitalGlobeNewswireAgrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., Oct. 15, 2025
- 1y agoKROSKeros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual MeetingGlobeNewswireLEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
- 1y agoKROSKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesGlobeNewswireLEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 1y agoKROSADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board RefreshmentPR NewswireADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros"...
- 1y agoKROSKeros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular DystrophyGlobeNewswireLEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
- 1y agoKROSKeros to Exclusively Prioritize the Clinical Advancement of KER-065GlobeNewswireCompany Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025
- 1y agoKROSKeros Therapeutics Reports Second Quarter 2025 Financial ResultsGlobeNewswireLEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 1y agoKROSKeros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of ElriterceptGlobeNewswireLEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
- 1y agoKROSADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return ProposalPR NewswireADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros"...
- 1y agoKROSKeros Announces Return of $375 Million in Excess Capital to StockholdersGlobeNewswireLEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 1y agoKROSKeros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireLEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
- 1y agoKROSKeros Therapeutics Announces TROPOS Topline Data and Corporate RestructuringGlobeNewswireDiscontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc.
- 1y agoKROSLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director NomineesGlobeNewswireKeros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1's Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of
- 1y agoKROSADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna SethPR NewswireADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros"...
- 1y agoKROSTAKKeros Therapeutics Highlights Commitment to Maximizing Stockholder ValueGlobeNewswireFiles Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting "FOR" Each of the Company's Highly Qualified Director Nominees LEXINGTON, Mass.,
- 1y agoKROSADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna SethPR NewswireADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the...
- 1y agoKROSKeros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare ConferenceGlobeNewswireLEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
- 1y agoKROSKeros Reinforces Commitment to Maximizing Stockholder ValueGlobeNewswireResponds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting "FOR" the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE
- 1y agoKROSADAR1 Capital Management Issues Open Letter to Keros Therapeutics StockholdersPR NewswireADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the...
- 1y agoKROSKeros Therapeutics Reports Recent First Quarter 2025 Financial ResultsGlobeNewswireLEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 1y agoKROSKeros Therapeutics Announces Review of Strategic AlternativesGlobeNewswireAdopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage
- 1y agoKROSKeros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy VolunteersGlobeNewswireTrial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in
- 1y agoKROSKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesGlobeNewswireLEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
- 1y agoKROSKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireLEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 1y agoKROSKeros Therapeutics to Present at the Guggenheim SMID Cap Biotech ConferenceGlobeNewswireLEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
- 1y agoKROSKirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)Business WireThe law firm of Kirby McInerney LLP is investigating potential claims against Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). The investigation concerns whether Keros and/or certain of its officers
- 1y agoKROSTAKKeros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance ElriterceptGlobeNewswireLEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 1y agoKROSKeros Therapeutics Announces Additional Update on the Phase 2 TROPOS TrialGlobeNewswireLEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel
- 1y agoKROSKeros Therapeutics Announces Update on the Phase 2 TROPOS TrialGlobeNewswireKeros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a
- 1y agoKROSKeros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and ExpositionGlobeNewswireElritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 weeksDurable clinical
- 1y agoKROSTAKTYO:4502Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros TherapeuticsBusiness Wire− Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis − Takeda to
- 1y agoKROSTAKKeros Therapeutics Announces Global License Agreement with Takeda to Advance ElriterceptGlobeNewswireKeros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered royalties on net sales
- 1y agoKROSKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesGlobeNewswireLEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel